Company / SG&A Expense
Lineage Cell Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$18.5M
FY2025
5-year range
$15.6M / $18.5M
FY2021-FY2025
Trend
+1.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $16M in FY2021 to $29M in FY2017.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of -5.1%.
Increased from $17M to $18M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.5%
- 5-Year CAGR
- -5.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.1%, indicating a declining trend.
- In FY2025, sg&a expense increased 1.6% year-over-year.
- Peak sg&a expense was recorded in FY2017.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.5M | +1.6% |
| FY2024 | $18.2M | +5.0% |
| FY2023 | $17.3M | -5.0% |
| FY2022 | $18.2M | +17.0% |
| FY2021 | $15.6M | -35.2% |
| FY2020 | $24.0M | -2.8% |
| FY2019 | $24.7M | +24.1% |
| FY2018 | $19.9M | -31.6% |
| FY2017 | $29.1M | +65.9% |
| FY2016 | $17.6M | +12.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026